Editorial Policy
Purpose
Content published on this hub is strictly educational and informational. Our goal is to translate scientific evidence into accessible language without making therapeutic or clinical promises.
Research phase separation
We clearly differentiate: (1) pre-clinical research (in vitro and animal models), (2) ongoing clinical trials (phases I, II, III) and (3) regulatory-approved use (ANVISA, FDA, EMA). This separation is maintained across all articles.
No therapeutic promises
We do not use language suggesting cure, guaranteed treatment or specific clinical outcomes. Terms like "revolutionize", "cure" or "offer hope" are avoided. When describing therapeutic potential, we indicate the evidence stage and its limitations.
Medical disclaimer
No content on this site replaces professional medical advice. Patients should consult their physicians before making treatment decisions.
Financial disclaimer
When we cover management, fundraising or unit economics of innovative companies, the content is educational and does not constitute financial or investment advice.
Sources and references
All articles include references from indexed journals, scientific society guidelines or official regulatory documents. We prioritize high-impact sources and recent publications.
Technical review
Articles are reviewed by professionals with backgrounds in health sciences, pharmacy or related fields before publication.
Confidentiality
We do not publish confidential or proprietary information from companies in the Axis Biotec ecosystem. Only public data is used.